Compared with warfarin, dabigatran and rivaroxaban linked to lower risk of adverse renal outcomes
Study of newer medications finds 16 percent receive too much or too little
Despite trend toward lower stroke risk with high dose
Most people with nonvalvular atrial fibrillation (NVAF) should be taking oral anticoagulants to prevent stroke.
Patients with heart valve replacements have greater rates of thromboembolic and bleeding complications after treatment with dabigatran vs. warfarin.
The FDA is alerting healthcare providers and patients of important storage and handling requirements for Pradaxa (dabigatran etexilate mesylate capsules; Boehringer Ingelheim).
Pradaxa (dabigatran etexilate capsules) 150mg, an oral direct thrombin inhibitor, will be made available by Boehringer Ingelheim on November 3, 2010.